{
  "docId": "019de075-746f-7643-8ae7-19646171e75b",
  "docSlug": "e49fd8f0d5e7ac656caa3720c9a74f92",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 28,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 9,
  "notes": "Clinical trial data showing individual patient responses over time.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-746f-7643-8ae7-19646171e75b/13",
  "deckHref": "/decks/019de075-746f-7643-8ae7-19646171e75b",
  "deckJsonHref": "/decks/019de075-746f-7643-8ae7-19646171e75b.json",
  "deckAnchorHref": "/decks/019de075-746f-7643-8ae7-19646171e75b#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Individual patient longitudinal biomarker charts",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cac7ef3b-d5d0-4331-8473-b77c7e1d0b9f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.78
      },
      "kind": "list",
      "text": "7 of 9 (78%) subjects remain off NA therapy for 44-64 weeks and all completed imdusiran treatment over 1½ years ago; Most subjects have maintained low HBV DNA levels off treatment; HBsAg remains between -0.8 and -1.6 log10 IU/mL below baseline values; NA discontinuation post-imdusiran treatment appears well tolerated with no ALT flares",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "385fa562-6e26-4f0a-86cd-414f20dfb956",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.28,
        "y": 0.093
      },
      "kind": "source-note",
      "text": "* Patient 53 restarted NA therapy at Investigator’s request after the NA d/c FU W20 visit (pink shaded area). ** Patient 58 restarted therapy after the NA d/c FU W36 visit (pink shaded area).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7553f1b1-f41e-4906-839f-9f8ca7b73413",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "AB-729-001: Imdusiran Shows Low Levels of HBV Biomarkers Persisting in cHBV Patients While Off-Treatment",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0866e01d-0100-4eea-aa4a-de87d9614e5a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 9,
      "beatId": "8558af21-b173-40d9-bee7-cbb86e4f3ca4",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The deck presents Arbutus Biopharma's pipeline, including Imdusiran, AB-161, and AB-101, as a promising approach to treating HBV",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 9,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "cf0f4444-bb37-4efd-b316-e8da602c5aea",
      "evidence": "The deck presents data and results from clinical trials for Imdusiran and other pipeline assets",
      "position": 1,
      "objective": "Showcase Arbutus Biopharma's pipeline as a solution to the HBV problem",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}